Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity

Journal of the American Veterinary Medical Association

Volumn 232, Issue 10, 2008, Pages 1496-1503

  Oyama, Mark A ^a   Fox, Philip R ^b   Rush, John E ^c   Rozanski, Elizabeth A ^c   Lesser, Mike ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ANIMAL MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY   (United States)

^d The case was managed at VCA Advanced Veterinary Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; N TERMINAL PROATRIAL NATRIURETIC PEPTIDE; N-TERMINAL PROATRIAL NATRIURETIC PEPTIDE; PROTEIN PRECURSOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CASE CONTROL STUDY; CONGESTIVE CARDIOMYOPATHY; DIFFERENTIAL DIAGNOSIS; DOG; DOG DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART DISEASE; HOSPITALIZATION; MALE; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALVULAR HEART DISEASE;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; DOG DISEASES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART DISEASES; HEART VALVE DISEASES; MALE; PROTEIN PRECURSORS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

ANIMALIA; CANIS FAMILIARIS;

EID: 43949088495     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.232.10.1496     Document Type: Article

References (35)

1. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684-H1689.
2. Hogenhuis J, Voors AA, Jaarsma T, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail 2007;9:787-794.
3. Goetze JP, Rehfeld JF, Videbaek R, et al. B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts. Eur J Heart Fail 2005;7:69-74.
4. Chen HH, Grantham JA, Schirger JA, et al. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000;36:1706-1712.
5. Lainchbury JG, Burnett JC Jr, Meyer D, et al. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 2000;278:H33-H40.
6. Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases (Erratum published in Congest Heart Fail 2005;11:102). Congest Heart Fail 2004;10(5 suppl 3):1-30.
7. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733-1739.
8. Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007;23:21-45.
9. Cardarelli R, Lumicao TG Jr. B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract 2003;16:327-333.
10. Mueller C, Breidthardt T, Laule-Kilian K, et al. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 2007;137:4-12.
11. Hutcheon SD, Gillespie ND, Struthers AD, et al. B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. Age Ageing 2002;31:295-301.
12. Takase H, Toriyama T, Sugiura T, et al. Brain natriuretic peptide detects cardiac abnormalities in mass screening. Eur J Clin Invest 2007;37:257-262.
13. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.
14. Asano K, Masuda K, Okumura M, et al. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. J Vet Med Sci 1999;61:523-529.
15. MacDonald KA, Kittleson MD, Munro C, et al. Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure. J Vet Intern Med 2003;17:172-177.
16. Oyama MA, Sisson DD, Solter PF. Prospective screening for occult cardiomyopathy in dogs by measurement of plasma atrial natriuretic peptide, B-type natriuretic peptide, and cardiac troponin-1 concentrations. Am J Vet Res 2007;68:42-47.
17. DeFrancesco TC, Rush JE, Rozanski EA, et al. Prospective clinical evaluation of an ELISA B-type natriuretic peptide assay in the diagnosis of congestive heart failure in dogs presenting with cough or dyspnea. J Vet Intern Med 2007;21:243-250.
18. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287-296.
19. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-337.
20. Mueller T, Gegenhuber A, Poelz W, et al. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004;341:41-48.
21. Alibay Y, Beauchet A, El Mahmoud R, et al. Analytical correlation between plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in patients presenting with dyspnea. Clin Biochem 2004;37:933-936.
22. Mueller T, Gegenhuber A, Poelz W, et al. Biochemical diagnosis of impaired left ventricular ejection fraction - comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin Chem Lab Med 2004;42:159-163.
23. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58: 1072-1083.
24. Hansson K, Haggstrom J, Kvart C, et al. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002;43:568-575.
25. Buchanan JW, Bücheier J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194-199.
26. Hansson K, Haggstrom J, Kvart C, et al. Interobserver variability of vertebral heart size measurements in dogs with normal and enlarged hearts. Vet Radiol Ultrasound 2005;46:122-130.
27. Lamb CR, Wikeley H, Boswood A, et al. Use of breed-specific ranges for the vertebral heart scale as an aid to the radiographic diagnosis of cardiac disease in dogs. Vet Rec 2001;148:707-711.
28. International Small Animal Cardiac Health Council. Appendix A: recommendations for diagnosis of heart disease and treatment of heart failure in small animals. In: Fox PR, Sisson DD, Moise NS, eds. Textbook of canine and feline cardiology. 2nd ed. Philadelphia: WB Saunders Co, 1999;883-901.
29. Metra M, Nodari S, Parrinello G, et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail 2007;9:776-786.
30. van Kimmenade RR, Pinto YM, Bayes-Genis A, et al. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006;98:386-390.
31. O'Hanlon R, O'Shea P, Ledwidge M, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007;13:50-55.
32. Abdulle AM, Nagelkerke NJ, Adem A, et al. Plasma N terminal pro-brain natriuretic peptide levels and its determinants in a multi-ethnic population. J Hum Hypertens 2007;21:647-653.
33. Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-751.
34. Eriksson AS, Jârvinen AK, Eklund KK, et al. Effect of age and body weight on neurohumoral variables in healthy Cavalier King Charles spaniels. Am J Vet Res 2001;62:1818-1824.
35. Baumwart RD, Meurs KM. Assessment of plasma brain natriuretic-peptide concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res 2005;66:2086-2089.